| Source: |
| Type: |
| Cognitive |
| 3612- | RES, | Resveratrol in Alzheimer's disease: a review of pathophysiology and therapeutic potential |
| - | Review, | AD, | NA |
| 3099- | RES, | Resveratrol and cognitive decline: a clinician perspective |
| - | Review, | Nor, | NA | - | NA, | AD, | NA |
| 3100- | RES, | Neuroprotective effects of resveratrol in Alzheimer disease pathology |
| - | Review, | AD, | NA |
| 4285- | RES, | Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy |
| - | in-vivo, | AD, | NA |
| 3729- | RF, | Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 3730- | RF, | Transcranial electromagnetic treatment against Alzheimer's disease: why it has the potential to trump Alzheimer's disease drug development |
| - | Review, | AD, | NA |
| 3731- | RF, | Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice |
| - | in-vivo, | AD, | NA |
| 3732- | RF, | Electromagnetic treatment to old Alzheimer's mice reverses β-amyloid deposition, modifies cerebral blood flow, and provides selected cognitive benefit |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3736- | RF, | Long-term electromagnetic pulse exposure induces Abeta deposition and cognitive dysfunction through oxidative stress and overexpression of APP and BACE1 |
| - | in-vivo, | AD, | NA |
| 3738- | RF, | Electromagnetic Field Stimulation Therapy for Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3461- | RF, | Electromagnetic Field Stimulation Therapy for Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3490- | RF, | Multidimensional insights into the repeated electromagnetic field stimulation and biosystems interaction in aging and age-related diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3616- | RosA, | Therapeutic effects of rosemary (Rosmarinus officinalis L.) and its active constituents on nervous system disorders |
| - | Review, | AD, | NA |
| 3617- | RosA, | Aroma, | Effect of aromatherapy on patients with Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 3621- | RosA, | Short-Term Study on the Effects of Rosemary on Cognitive Function in an Elderly Population |
| - | Trial, | AD, | NA |
| 3020- | RosA, | Protective Effect of Rosmarinic Acid on Endotoxin-Induced Neuronal Damage Through Modulating GRP78/PERK/MANF Pathway |
| - | in-vivo, | Nor, | NA | - | in-vitro, | NA, | SH-SY5Y |
| 3022- | RosA, | Rosmarinic acid against cognitive impairment via RACK1/HIF-1α regulated microglial polarization in sepsis-surviving mice |
| - | in-vitro, | Sepsis, | NA |
| 3937- | RT, | Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer’s disease |
| - | in-vivo, | AD, | NA |
| 3935- | RT, | Sodium rutin ameliorates Alzheimer's disease-like pathology by enhancing microglial amyloid-β clearance |
| - | in-vivo, | AD, | NA |
| 3934- | RT, | Rutin: A Potential Therapeutic Agent for Alzheimer Disease |
| - | Review, | AD, | NA |
| 3933- | RT, | The Pharmacological Potential of Rutin |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | Arthritis, | NA |
| 3932- | RT, | Rutin as a Natural Therapy for Alzheimer's Disease: Insights into its Mechanisms of Action |
| - | Review, | AD, | NA |
| 3638- | Sage, | Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial |
| - | Trial, | AD, | NA |
| 3639- | Sage, | Pharmacological properties of Salvia officinalis and its components |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3641- | Sage, | Systematic Review of Clinical Trials Assessing Pharmacological Properties of Salvia Species on Memory, Cognitive Impairment and Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3642- | Sage, | Chronic Supplementation with a Mix of Salvia officinalis and Salvia lavandulaefolia Improves Morris Water Maze Learning in Normal Adult C57Bl/6J Mice |
| - | in-vivo, | AD, | NA |
| 3643- | Sage, | Effects of cholinesterase inhibiting sage (Salvia officinalis) on mood, anxiety and performance on a psychological stressor battery |
| - | Human, | Nor, | NA |
| 3644- | Sage, | Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers |
| - | Human, | AD, | NA |
| 4217- | Sage, | RosA, | Aroma, | Neuroprotective Potential of Aromatic Herbs: Rosemary, Sage, and Lavender |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3939- | SAMe, | VitB12, | ALC, | Efficacy of a Vitamin/Nutriceutical Formulation for Moderate-stage to Later-stage Alzheimer's disease: A Placebo-controlled Pilot Study |
| - | Trial, | NA, | NA |
| 4085- | Se, | Role of micronutrients in Alzheimer's disease: Review of available evidence |
| - | Review, | AD, | NA |
| 6063- | SeNPs, | Large Amino Acid Mimicking Selenium-Doped Carbon Quantum Dots for Multi-Target Therapy of Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 6061- | SeNPs, | MET, | Multifunctional mesoporous nanoselenium delivery of metformin breaks the vicious cycle of neuroinflammation and ROS, promotes microglia regulation and alleviates Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| - | Review, | AD, | NA |
| 6048- | SeNPs, | Unravelling the in vitro and in vivo potential of selenium nanoparticles in Alzheimer's disease: A bioanalytical review |
| - | Review, | AD, | NA |
| 4448- | SeNPs, | Selenium Nanoparticles: A Comprehensive Examination of Synthesis Techniques and Their Diverse Applications in Medical Research and Toxicology Studies |
| - | Review, | Nor, | NA |
| 4189- | Sesame, | Sesame oil mitigates memory impairment, oxidative stress, and neurodegeneration in a rat model of Alzheimer's disease. A pivotal role of NF-κB/p38MAPK/BDNF/PPAR-γ pathways |
| - | in-vivo, | AD, | NA |
| 3663- | SFN, | Efficacy of Sulforaphane in Neurodegenerative Diseases |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3662- | SFN, | Sulforaphane Inhibits the Generation of Amyloid-β Oligomer and Promotes Spatial Learning and Memory in Alzheimer's Disease (PS1V97L) Transgenic Mice |
| - | in-vivo, | AD, | NA |
| 3661- | SFN, | Beneficial Effects of Sulforaphane Treatment in Alzheimer's Disease May Be Mediated through Reduced HDAC1/3 and Increased P75NTR Expression |
| - | in-vitro, | AD, | NA |
| 3658- | SFN, | Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 2168- | SFN, | Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model |
| - | in-vivo, | AD, | NA |
| 1452- | SFN, | Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells |
| - | in-vitro, | GC, | AGS |
| 3946- | Shank, | Phytochemical Profile, Pharmacological Attributes and Medicinal Properties of Convolvulus prostratus – A Cognitive Enhancer Herb for the Management of Neurodegenerative Etiologies |
| - | Review, | AD, | NA |
| 3321- | SIL, | cognitive_vitality_media/Silymarin-Cognitive-Vitality-For-Researchers.pdf">Silymarin (Milk thistle) |
| - | Review, | AD, | NA |
| 3319- | SIL, | Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 3318- | SIL, | Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3316- | SIL, | Chemo, | Silymarin Nanoparticles Counteract Cognitive Impairment Induced by Doxorubicin and Cyclophosphamide in Rats; Insights into Mitochondrial Dysfunction and Nrf2/HO-1 Axis |
| 3653- | SIL, | Silibinin ameliorates Aβ25-35-induced memory deficits in rats by modulating autophagy and attenuating neuroinflammation as well as oxidative stress |
| - | in-vivo, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:557 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid